Genmab — Februar 2020
-
Ka ikke se meget lemminge effekt.. casen er naturligvis intakt men hvis kursen kommer for langt frem i forhold til, hvor forretningen er, synes jeg det er helt ok at tage noget gevinst.. hvis salget var yderligere accelereret kunne man måske forsvare at kursen ku holdes på det voldsomt høje niveau.. men det skete ikke.. absolut ingen katastrofe! Men jeg tager nu gevinst for første gang i vel 15 år eller sådan noget lignene.
-
Genmab Publishes 2019 Annual Report
Company Announcement Copenhagen, Denmark; February 19, 2020 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2019....
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

